In this cohort, patients with breast cancer with high WAVE2 expression levels in their tumors had worst clinical outcomes when compared with patients with low WAVE2 levels, and patients with high tumor WAVE2 mRNA levels have an average reduced survival of 36 months (Fig. 1G), while those with high tumor WAVE2 protein levels have an average reduced survival of 52 months (Fig. 1H) when compared with patients with low tumor WAVE2. This evidence concerns the gene WASF2 and neoplasm.